Meet The Professors

Dr Andrew J Armstrong from the Duke Cancer Institute in Durham, North Carolina, and Dr Scott T Tagawa from Weill Cornell Medicine Meyer Cancer Center in New York, New York, discuss the selection and sequencing of therapy for patients with prostate cancer and summarize major advances in the treatment landscape over the past year.CME information and select publications here.

Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.CME information and select publications here.

Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer.CME information and select publications here.

Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer. CME information and select publications here.

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia, and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.

Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer. CME information and select publications here.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here.

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here.

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.CME information and select publications here.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Nikhil I Khushalani from Moffitt Cancer Center in Tampa, Florida, Dr Soo J Park from the UC San Diego Moores Cancer Center in California, Dr Vishal Anil Patel from the GW Cancer Center in Washington, DC, and Dr Evan Wuthrick, also from Moffitt Cancer Center, discusses recent updates on available and novel treatment strategies for nonmelanoma skin cancers.CME information and select publications here.

Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.

Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.CME information and select publications here.

Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors. CME information and select publications here.

Dr Matthew Milowsky from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, comments on real patient cases of metastatic urothelial bladder cancer presented by Dr Jacqueline T Brown from the Emory University School of Medicine in Atlanta, Georgia and Dr Nazli Dizman from The University of Texas MD Anderson Cancer Center in Houston. CME information and select publications here.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic’s Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.CME information and select publications here.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.